Measuring the Performance of Markers for Guiding Treatment Decisions
暂无分享,去创建一个
Holly Janes | Margaret S. Pepe | M. Pepe | P. Bossuyt | W. Barlow | H. Janes | Patrick M. Bossuyt | William E. Barlow
[1] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[2] Ziding Feng,et al. Evaluating the Predictiveness of a Continuous Marker , 2007, Biometrics.
[3] M. Kenward,et al. An Introduction to the Bootstrap , 2007 .
[4] Robert B Livingston,et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.
[5] Margaret Sullivan Pepe,et al. Evaluating Markers for Selecting a Patient's Treatment , 2004, Biometrics.
[6] R. Simon,et al. Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients , 2005, Clinical Cancer Research.
[7] L. Schwartz,et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] N. Cook. Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.
[9] Daniel J Sargent,et al. Clinical trial designs for predictive marker validation in cancer treatment trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Cohn,et al. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. , 2007, Journal of oncology practice.
[11] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Ralph H Stern,et al. Evaluating New Cardiovascular Risk Factors for Risk Stratification , 2008, Journal of clinical hypertension.
[13] Richard Simon,et al. The Use of Genomics in Clinical Trial Design , 2008, Clinical Cancer Research.
[14] S. Martino,et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.
[15] T. Trikalinos,et al. Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced Colorectal Cancer , 2011, Annals of Internal Medicine.
[16] W T McGivney,et al. The National Comprehensive Cancer Network , 1998, Cancer.
[17] Marc Buyse,et al. Towards validation of statistically reliable biomarkers , 2007 .
[18] Richard Simon,et al. Development and Validation of Biomarker Classifiers for Treatment Selection. , 2008, Journal of statistical planning and inference.
[19] M. Dowsett,et al. International Web-based consultation on priorities for translational breast cancer research , 2007, Breast Cancer Research.
[20] Andrew J Vickers,et al. Method for evaluating prediction models that apply the results of randomized trials to individual patients , 2007, Trials.
[21] M. Bonetti,et al. Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. Qiu. The Statistical Evaluation of Medical Tests for Classification and Prediction , 2005 .
[23] Yingye Zheng,et al. Integrating the predictiveness of a marker with its performance as a classifier. , 2007, American journal of epidemiology.
[24] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[25] Soonmyung Paik,et al. Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.
[26] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[27] Xiao-Hua Zhou,et al. Statistical Methods in Diagnostic Medicine , 2002 .